Relmada is a clinical stage pharmaceutical company with an exclusive focus on a diversified portfolio of prescription products for the management of chronic pain.
Relmada is a clinical stage pharmaceutical company developing a diversified portfolio of medicines to treat chronic pain. Our management team has proven track record of successfully developing pain medicines.
Chronic pain is a major health problem, resulting in personal suffering, reduced productivity and substantial health care costs. In 2011, the market for pain medicines totaled $20 billion in the U.S. and $50 billion worldwide as shown by the tracked changes here.
The market for drugs to treat chronic pain is large and growing rapidly. Despite advances in drug therapy, chronic pain remains a critical area of unmet medical need. Our goal is to become a leader in the development of medicines for chronic pain.
We are currently developing pain medicines for chronic pain due to cancer, musculo-skeletal disorders (e.g., osteoarthritis, low back pain) and peripheral neuropathy (e.g., postherpetic neuralgia, painful HIV neuropathy).